The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anhalt, G. J.
Right arrow Articles by Eaglstein, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anhalt, G. J.
Right arrow Articles by Eaglstein, N. F.

The Journal of Immunology, Vol 137, Issue 9 2835-2840, Copyright © 1986 by American Association of Immunologists


ARTICLES

Defining the role of complement in experimental pemphigus vulgaris in mice

GJ Anhalt, GO Till, LA Diaz, RS Labib, HP Patel and NF Eaglstein

Parenteral passive transfer of human pemphigus vulgaris IgG (PV IgG) into neonatal mice reproduces the cutaneous disease. We used this model to study the role of complement in the development of acantholysis in three steps. Peptic F(ab')2 fragments were prepared from PV IgG and were injected into seven newborn mice, and all animals developed acantholytic skin blisters without local complement activation, as shown by direct immunofluorescence. These fragments were reduced and alkylated to produce Fab' fragments with equivalent in vitro binding activity. The monovalent fragments were given in an identical fashion to five littermates but failed to produce disease even though they were bound in the epidermis in vivo. Intact PV IgG was injected in 20 genetically C5-deficient neonates (B10-D2-OSN strain) and 20 control neonates (B10-D2-NSN, normal complementemic). Extensive blistering, with a positive Nikolsky sign, was produced in all 40 animals. PV IgG was given to 34 BALB/c neonates that were complement depleted by pretreatment with cobra venom factor (CoF) for 24 hr, and to 38 untreated neonates from the same litters. There was no difference in the disease produced after CoF treatment in animals that received high doses of PV IgG (5 to 15 mg/g/day). In animals receiving 2.5 mg PV IgG/g/day, blister formation was delayed and the final extent of the cutaneous lesions was less in CoF-treated mice (n = 12) than in normal complementemic controls (n = 12, p less than 0.02). These results show that complement activation is not an essential mechanism in PV IgG- induced acantholysis in vivo, but it does have an amplifying effect on the development of cutaneous lesions under certain conditions, and lesions can be induced in vivo by bivalent F(ab')2 fragments of PV IgG, but not by the monovalent Fab' fragments, suggesting that cross-linking of the cell surface antigen is an initiating signal in acantholysis.


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
P. Berkowitz, M. Chua, Z. Liu, L. A. Diaz, and D. S. Rubenstein
Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin
Am. J. Pathol., December 1, 2008; 173(6): 1628 - 1636.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Mihai, M. T. Chiriac, K. Takahashi, J. M. Thurman, V. M. Holers, D. Zillikens, M. Botto, and C. Sitaru
The Alternative Pathway of Complement Activation Is Critical for Blister Induction in Experimental Epidermolysis Bullosa Acquisita
J. Immunol., May 15, 2007; 178(10): 6514 - 6521.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Sitaru, M. T. Chiriac, S. Mihai, J. Buning, A. Gebert, A. Ishiko, and D. Zillikens
Induction of Complement-Fixing Autoantibodies against Type VII Collagen Results in Subepidermal Blistering in Mice.
J. Immunol., September 1, 2006; 177(5): 3461 - 3468.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Berkowitz, P. Hu, S. Warren, Z. Liu, L. A. Diaz, and D. S. Rubenstein
p38MAPK inhibition prevents disease in pemphigus vulgaris mice
PNAS, August 22, 2006; 103(34): 12855 - 12860.
[Abstract] [Full Text] [PDF]


Home page
fake Crit Rev Oral Biol MedHome page
E. Dabelsteen
Molecular Biological Aspects of Acquired Bullous Diseases
Critical Reviews in Oral Biology & Medicine, January 1, 1998; 9(2): 162 - 178.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.